Arcutis Biotherapeutics, Inc. (ARQT) Cash Flow Statement

The gap between net income and operating cash flow in Q2 2026 is primarily attributable to a $16.2M working capital outflow, which offset the positive earnings. This pattern indicates that while the company has reached a profitability inflection, cash generation is not yet matching reported earnings, likely due to timing of receivables and inventory. Investors should monitor whether working capital drags persist as revenue scales, as sustained divergence would signal lower earnings quality.

The trajectory of free cash flow shows a dramatic improvement, with the last two quarters (Q1 and Q2 2026) both positive, contrasting with negative FCF in all of 2024 and most of 2025. However, the volatility is high, as Q3 2025 saw FCF of -$1.8M despite positive net income, underscoring the lumpy nature of working capital. The positive FCF margin of 9.6% in Q2 2026, while still modest, suggests that the company is beginning to convert its high gross margins into cash, but sustainability remains unproven given the thin cash balance.

The extremely low capex relative to revenue indicates that Arcutis does not require significant fixed asset investment to grow, which is typical for a specialty pharma with outsourced manufacturing. This low capital intensity means that once operating leverage is achieved, a high proportion of incremental revenue should flow to free cash flow. However, the lack of capex also implies that the company is not investing in internal manufacturing capacity, which could become a bottleneck if demand outpaces third-party supply agreements.

The working capital line has been the primary source of cash flow volatility, with large negative changes in several quarters (Q3 2025, Q2 2026) and positive changes in others (Q1 2026, Q2 2025). This pattern suggests that Arcutis is experiencing timing mismatches between revenue recognition and cash collections, possibly due to wholesaler stocking and payer rebates. The consistent negative working capital changes in quarters with strong revenue growth may indicate that the company is extending credit or building inventory to support launch, which could pressure cash flow in the near term.

The absence of capital returns is consistent with a company in a growth phase, prioritizing reinvestment in its sales force and pipeline over shareholder distributions. Given the thin cash balance of $42.9M, the lack of buybacks or dividends is prudent, but it also means that investors cannot rely on a cash return cushion. The company's capital deployment is entirely focused on organic growth, which is appropriate if the ZORYVE franchise continues to scale, but it leaves little margin for error if revenue growth stalls.

The cumulative divergence between net income and operating cash flow is significant, with net losses exceeding cash burn by roughly $81M. This gap is largely explained by stock-based compensation, which totaled over $100M in the period, a non-cash expense that reduces net income but does not impact cash. This suggests that the company's cash burn is less severe than its accounting losses imply, but it also highlights the dilutive nature of employee compensation. As the company approaches profitability, the reduction in SBC as a percentage of revenue will be critical to closing the gap between earnings and cash generation.